Drug Trial Radar · NCT07680439
Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
75
Planned (sponsor's estimate)
Start
Sep 4, 2026
Primary completion
Oct 2028
Study completion Jul 2030
Sponsor
- Lead sponsor
- BrainChild Bio, IncIndustry
- Sponsor type
- Industry
- First posted
- Jul 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 year, up to 26 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate BCB-276, an investigational B7-H3-targeted Chimeric Antigen Receptor (CAR) T cell therapy, in children and young adults with diffuse intrinsic pontine glioma (DIPG). DIPG is a rare and aggressive brain tumor with limited treatment options. CAR T cell therapy uses a patient's own immune cells that are changed in a laboratory to recognize and attack cancer cells. The purpose of this study is to determine whether BCB-276, when given after completion of standard radiation therapy, is safe and can improve survival for patients with DIPG. To participate, individuals must be between 1 and 26 years of age when they join the study, have a diagnosis of DIPG, and enroll for treatment within 6 weeks of completing initial radiation therapy. Participants must not have received prior anti-cancer therapy beyond radiation with or without temozolomide prior to joining this study. BCB-276 is administered intraventricularly (into the fluid around the brain), which requires placement of a catheter for treatment. BCB-276 is given every 2 weeks at a research center over a period of several months (approximately 7-8 months). Participation includes travel to a study site, procedures to support treatment administration, sample collection, and ongoing monitoring for safety and effectiveness, with follow-up visits lasting up to about 2 years.
Conditions
- Diffuse Intrinsic Pontine Glioma
- DIPG
- Brain Tumor
- CNS Tumor
- Central Nervous System Tumor
- Pediatric Cancer
- Adult Cancer Patients
- CNS Tumor, Childhood
- CNS Tumor, Adult
- Brainstem Glioma
- Diffuse Midline Glioma
- DMG
Interventions
BCB-276Biological
Following completion of standard radiation therapy, eligible participants with DIPG will undergo leukapheresis, a procedure to collect white blood cells used to manufacture BCB-276, an autologous CAR T cell therapy made from the participant's own immune cells designed to target B7-H3. All eligible participants will receive up to 15 intraventricular administrations of BCB-276 every 2 weeks for an approximate total duration of 30 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall SurvivalTime frame: Overall Survival (OS) as defined as time from the date of enrollment to death from any cause (up to 24 months from date of enrollment).
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Children's Hospital Los Angeles
Los Angeles, California · Not yet recruiting
Children's Healthcare of Atlanta
Atlanta, Georgia · Recruiting
Lurie Children's Hospital
Chicago, Illinois · Recruiting
Nationwide Children's Hospital
Columbus, Ohio · Not yet recruiting
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania · Recruiting
Seattle Children's Hospital
Seattle, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.